Christopher Jay Richards, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cystic Fibrosis | 5 | 2023 | 1285 | 1.070 |
Why?
|
Clothing | 1 | 2024 | 97 | 0.870 |
Why?
|
Opiate Alkaloids | 1 | 2023 | 28 | 0.850 |
Why?
|
Bronchiectasis | 4 | 2024 | 139 | 0.760 |
Why?
|
Pulmonary Eosinophilia | 1 | 2013 | 78 | 0.420 |
Why?
|
Progestins | 1 | 2013 | 301 | 0.380 |
Why?
|
Tetracyclines | 1 | 2010 | 64 | 0.360 |
Why?
|
Internal Medicine | 1 | 2017 | 1051 | 0.330 |
Why?
|
Progesterone | 1 | 2013 | 742 | 0.320 |
Why?
|
Education, Medical, Undergraduate | 1 | 2017 | 1070 | 0.290 |
Why?
|
Substance-Related Disorders | 1 | 2023 | 4420 | 0.270 |
Why?
|
Pyrroles | 2 | 2012 | 1125 | 0.260 |
Why?
|
Drug Hypersensitivity | 1 | 2013 | 917 | 0.230 |
Why?
|
Indoles | 2 | 2012 | 1833 | 0.230 |
Why?
|
Anti-Infective Agents | 1 | 2010 | 983 | 0.210 |
Why?
|
Finite Element Analysis | 1 | 2024 | 438 | 0.190 |
Why?
|
Clinical Competence | 1 | 2017 | 4793 | 0.180 |
Why?
|
Pressure | 1 | 2024 | 1154 | 0.180 |
Why?
|
Hyperoxia | 1 | 2022 | 258 | 0.180 |
Why?
|
Registries | 3 | 2024 | 8225 | 0.170 |
Why?
|
Pregnancy Complications | 1 | 2013 | 2947 | 0.160 |
Why?
|
Antineoplastic Agents | 3 | 2012 | 13642 | 0.150 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2020 | 445 | 0.140 |
Why?
|
Internship and Residency | 1 | 2017 | 5882 | 0.140 |
Why?
|
Sputum | 1 | 2018 | 506 | 0.130 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3165 | 0.130 |
Why?
|
Calixarenes | 2 | 2005 | 3 | 0.130 |
Why?
|
Macrocyclic Compounds | 2 | 2005 | 68 | 0.120 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4251 | 0.120 |
Why?
|
Staphylococcal Infections | 1 | 2022 | 1407 | 0.110 |
Why?
|
Lung | 3 | 2022 | 10002 | 0.110 |
Why?
|
Injections, Intramuscular | 1 | 2013 | 554 | 0.100 |
Why?
|
Methylprednisolone | 1 | 2013 | 385 | 0.100 |
Why?
|
Mycobacterium avium Complex | 2 | 2023 | 60 | 0.100 |
Why?
|
Patient Care | 1 | 2017 | 622 | 0.090 |
Why?
|
Clinical Clerkship | 1 | 2017 | 564 | 0.090 |
Why?
|
Lung Transplantation | 1 | 2020 | 1310 | 0.090 |
Why?
|
Influenza, Human | 1 | 2020 | 1521 | 0.080 |
Why?
|
Hypertension, Pulmonary | 1 | 2020 | 1578 | 0.080 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2011 | 629 | 0.080 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 664 | 0.080 |
Why?
|
Cellulose | 1 | 2008 | 118 | 0.080 |
Why?
|
Emergency Medicine | 1 | 2017 | 1198 | 0.070 |
Why?
|
Sarcoma, Kaposi | 1 | 2010 | 374 | 0.070 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 857 | 0.070 |
Why?
|
Heart Failure | 1 | 2011 | 11671 | 0.070 |
Why?
|
Periodontal Diseases | 1 | 2010 | 451 | 0.070 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.070 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14608 | 0.070 |
Why?
|
Humans | 16 | 2024 | 761596 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4016 | 0.060 |
Why?
|
Cyclodextrins | 1 | 2005 | 66 | 0.060 |
Why?
|
Adult | 5 | 2024 | 221210 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1809 | 0.060 |
Why?
|
Curriculum | 1 | 2017 | 3743 | 0.050 |
Why?
|
Radiography | 1 | 2013 | 6965 | 0.050 |
Why?
|
Female | 7 | 2024 | 392705 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2019 | 64685 | 0.040 |
Why?
|
Risk Factors | 2 | 2019 | 74213 | 0.040 |
Why?
|
Prospective Studies | 1 | 2023 | 54423 | 0.040 |
Why?
|
Male | 5 | 2024 | 360846 | 0.040 |
Why?
|
Polymers | 1 | 2005 | 1616 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2012 | 10212 | 0.040 |
Why?
|
Clinical Trials as Topic | 2 | 2010 | 8002 | 0.040 |
Why?
|
Survival Rate | 1 | 2011 | 12723 | 0.040 |
Why?
|
New England | 1 | 2020 | 1054 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2018 | 376 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5672 | 0.030 |
Why?
|
Forced Expiratory Volume | 1 | 2020 | 1814 | 0.030 |
Why?
|
Adolescent | 1 | 2023 | 88326 | 0.030 |
Why?
|
Cough | 1 | 2018 | 594 | 0.030 |
Why?
|
Pseudomonas aeruginosa | 1 | 2022 | 1277 | 0.030 |
Why?
|
Molecular Conformation | 2 | 2005 | 544 | 0.030 |
Why?
|
Incidence | 1 | 2011 | 21355 | 0.030 |
Why?
|
Patient Preference | 1 | 2020 | 927 | 0.030 |
Why?
|
Neoplasms | 2 | 2012 | 22173 | 0.020 |
Why?
|
Heterozygote | 1 | 2018 | 2787 | 0.020 |
Why?
|
Pregnancy | 1 | 2013 | 29890 | 0.020 |
Why?
|
Bacteria | 1 | 2022 | 2199 | 0.020 |
Why?
|
Benzenesulfonates | 1 | 2012 | 166 | 0.020 |
Why?
|
Middle Aged | 4 | 2024 | 220921 | 0.020 |
Why?
|
HIV-1 | 1 | 2008 | 6863 | 0.020 |
Why?
|
Oxygen | 1 | 2022 | 4227 | 0.020 |
Why?
|
Indazoles | 1 | 2012 | 304 | 0.020 |
Why?
|
Aged | 3 | 2024 | 169310 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2011 | 39106 | 0.020 |
Why?
|
Niacinamide | 1 | 2012 | 413 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2024 | 12463 | 0.020 |
Why?
|
Sinusitis | 1 | 2018 | 991 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2012 | 529 | 0.020 |
Why?
|
Disease Progression | 1 | 2024 | 13510 | 0.020 |
Why?
|
United States | 2 | 2024 | 72340 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2011 | 58984 | 0.020 |
Why?
|
Isomerism | 1 | 2005 | 197 | 0.020 |
Why?
|
Lanthanoid Series Elements | 1 | 2005 | 17 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2005 | 3769 | 0.020 |
Why?
|
Indicators and Reagents | 1 | 2005 | 462 | 0.010 |
Why?
|
Cations | 1 | 2005 | 238 | 0.010 |
Why?
|
Hospitalization | 1 | 2024 | 10721 | 0.010 |
Why?
|
Stereoisomerism | 1 | 2005 | 614 | 0.010 |
Why?
|
Solvents | 1 | 2005 | 295 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2018 | 12973 | 0.010 |
Why?
|
Proline | 1 | 2005 | 457 | 0.010 |
Why?
|
Sulfonamides | 1 | 2012 | 1979 | 0.010 |
Why?
|
HIV Infections | 1 | 2008 | 17354 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2008 | 1844 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41495 | 0.010 |
Why?
|
Virus Replication | 1 | 2008 | 2435 | 0.010 |
Why?
|
Pyridines | 1 | 2012 | 2875 | 0.010 |
Why?
|
Pyrimidines | 1 | 2012 | 3028 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2008 | 10766 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2018 | 20568 | 0.010 |
Why?
|
Models, Molecular | 1 | 2005 | 5439 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2023 | 80647 | 0.010 |
Why?
|
Mutation | 1 | 2018 | 30053 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2008 | 18966 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2008 | 4527 | 0.010 |
Why?
|